Summary: The Guardian reports on the psychedelic renaissance in Australia, profiling the experiences of several mental health professionals who are undergoing training in psychedelic-assisted therapy and highlighting the decision of Australia’s federal government “to back psychedelic clinical trials with $15m.”
“That announcement followed a growing worldwide interest and positive research developments: at the forefront is the US-based Multidisciplinary Association for Psychedelic Studies [MAPS], which has been conducting trials for MDMA-assisted psychotherapy for PTSD since 2011.”
Originally appearing here.
